Mode
Text Size
Log in / Sign up
N/A Completed N=12 Treatment

The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)

Source: ClinicalTrials.gov NCT01958294 ↗
Enrolled (actual)
12
Serious AEs
16.7%
Results posted
Jan 2020
Primary outcomePrimary: Composite of Any Stroke, Myocardial Infarction and Death — 1; 0; 0 participants

Summary

The LOTUS Study is intended to demonstrate the usability of the MICHI Neuroprotection System (MICHI NPS) or MICHI Neuroprotection System with filter (MICHI NPS+f) for use in subjects who are candidates for Carotid Artery Stenting (CAS). It is a prospective, single arm study in which a maximum of 30 study subjects, and a run-in enrollment of up to 10 subjects will be followed immediately post-op and at 30 days.

Outcome Measures

OutcomeResultp-value
PRIMARY
Composite of Any Stroke, Myocardial Infarction and Death
1; 0; 0
SECONDARY
Acute Device Success
10
SECONDARY
Procedural Success
9

Eligibility Criteria

Inclusion Criteria

  • Subject must be > 21 years of age.
  • Subject has the ability to understand and cooperate with study procedures and agrees to return for all required follow-up visits, tests, and exams.
  • International Normalized Ratio (INR) must be ≤ 1.5 at the time of the procedure (subjects taking warfarin may be included if their dose is tapered prior to the procedure to meet the inclusion criterion. Dose may be returned to a therapeutic level after the procedure).
  • The subject must sign a written informed consent prior to the procedure, using a form that is approved by the local medical Ethics Committee (EC).
  • The life expectancy of the subject is at least one year.
  • The subject has a lesion located in the internal carotid artery (ICA); the carotid bifurcation may be involved.
  • The subject must have a minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, computed axial tomographic (CT) angiography or magnetic resonance (MR) angiography.

Exclusion Criteria

  • The subject is participating in another investigational study that would interfere with the conduct or result of this study.
  • The subject has dementia or a neurological illness that may confound the neurological evaluation.
  • Presence of any one of the following anatomic risk factors:
  • Previous radiation treatment to the neck or radical neck dissection
  • Tracheostomy or tracheal stoma
  • Laryngectomy
  • Contralateral laryngeal nerve palsy
  • Severe tandem lesions
  • Inability to extend the head due to cervical arthritis or other cervical disorders
  • Total occlusion of the target vessel.
  • There is an existing, previously placed stent in the target artery.
  • The subject has a known life-threatening allergy to the contrast media that cannot be treated.
  • Subject has history of intolerance or allergic reaction to any of the study medications including aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), prasugrel heparin or bivalirudin (Angiomax™). Subjects must be able to tolerate a combination of aspirin and clopidogrel/ticlopidine or prasugrel.
  • The subject has a gastrointestinal bleed that would interfere with antiplatelet therapy.
  • The subject has known cardiac sources of emboli.
  • Subject has Hemoglobin (Hgb) less than 8 gm/dL (unless on dialysis), platelet count 250, or if the subject will refuse blood transfusions.
  • The subject has atherosclerotic disease involving the ipsilateral common carotid artery (CCA) that precludes safe placement of the sheath.
  • The subject has abnormal angiographic findings other than that of the target lesion that indicate the subject is at risk for a stroke, such as: ipsilateral arterial stenosis greater in severity than the target lesion, cerebral aneurysm, or arteriovenous malformation of the cerebral vasculature.
  • There is evidence of a carotid artery dissection prior to the initiation of the procedure.
  • There is an angiographically visible thrombus.
  • There is any condition that precludes proper angiographic assessment or makes percutaneous arterial access unsafe, e.g. morbid obesity, sustained systolic blood pressure > 180 mm Hg, tortuosity, occlusive disease, vessel anatomy or aortic arch anatomy.
  • Occlusion (TIMI 0 flow), or string sign of the ipsilateral common or internal carotid artery.
  • There is evidence of bilateral carotid stenosis that would require intervention within 30 days of procedure.
  • There is evidence of a major stroke (NIHSS ≥10) within the previous 30 days of the procedure or the patient is considered, by the investigator, to be at high risk for hemorrhagic stroke.
  • There is a planned treatment of a non-target lesion within 30 days post procedure.
  • There is a history of intracranial hemorrhage within the previous 3 months, including hemorrhagic transformation of an ischemic stroke.
  • There is history of an ipsilateral stroke with fluctuating neurologic symptoms within one year prior to the procedure.
  • Female subjects who are p
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01958294). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search